Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer

References

• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637–658. doi:10.1038/nrc.2017.84
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer fact sheet, 2018 [Internet]. World Health Organ Cancer Fact Sheet 2018. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300. doi:10.21037/tlcr.2016.06.07
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5(Suppl. 4):S389–S396. doi:10.3978/j.issn.2072-1439.2013.07.10
   PubMed Web of Science ®Google Scholar
• Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13:58. doi:10.1186/s13045-020-00881-7
   PubMed Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–774. doi:10.1038/nrc2947
   PubMed Web of Science ®Google Scholar
• Nan X, Xie C, Yu X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8:75712–75726. doi:10.18632/oncotarget.20095
   PubMedGoogle Scholar
• Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med. 2017;3:76. doi:10.3389/fmed.2016.00076
   PubMed Web of Science ®Google Scholar
• Li H-S, Yang G-J, Cai Y, et al. Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: a dual-center, single-arm, ambispective cohort study in China. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.919652
   Google Scholar
• Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–1466. doi:10.1016/S1470-2045(17)30608-3
   PubMed Web of Science ®Google Scholar
• U.S. FDA approves VIZIMPRO® (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Accessed June 6 2024. https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer
   Google Scholar
• Wang X, Huang A, Lu Y, et al. Drug-induced liver injury associated with dacomitinib: a case report. Front Oncol. 2022;12. doi:10.3389/fonc.2022.979462
   Google Scholar
• Vizimpro [Internet]. 2023. Available from: https://www.vizimpro.com/
   Google Scholar
• Storti C, Le Noci V, Sommariva M, Tagliabue E, Balsari A, Sfondrini L. Aerosol delivery in the treatment of lung cancer. Current Cancer Drug Targets. 2015;15:604–612. doi:10.2174/1568009615666150602143751
   PubMedGoogle Scholar
• Kuehl PJ, Yingling CM, Dubose D, et al. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug Deliv. 2021;28:767–775. doi:10.1080/10717544.2021.1912209
   PubMed Web of Science ®Google Scholar
• Sawant S, Patil S, Shukla S, et al. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. Drug Deliv Transl Res. 2021; 12:2474–2487. doi:10.1007/s13346-021-01088-0
   PubMedGoogle Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. Drug Deliv Res Eur. 2012;161:505–522. doi:10.1016/j.jconrel.2012.01.043
   Google Scholar
• Yadav B, Chauhan M, Shekhar S, et al. RGD-decorated PLGA nanoparticles improved effectiveness and safety of cisplatin for lung cancer therapy. Int J Pharm. 2023;633:122587. doi:10.1016/j.ijpharm.2023.122587
   PubMedGoogle Scholar
• Druvasarika B, Patil SM, Kunda NK. Formulation development of inhalable dacomitinib polymeric nanoparticles for non-small cell lung cancer treatment. 2024. Available from: https://ddl-conference.com/ddl2021/conference-papers/formulation-development-of-inhalable-dacomitinib-polymeric-nanoparticles-for-non-small-cell-lung-cancer-treatment/
   Google Scholar
• Gasparini G, Kosvintsev SR, Stillwell MT, et al. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Colloids Surf B Biointerfaces. 2008;61:199–207. doi:10.1016/j.colsurfb.2007.08.011
   PubMed Web of Science ®Google Scholar
• Patil SM, Sawant SS, Kunda NK. Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC). Int J Pharm. 2021;607:121046. doi:10.1016/j.ijpharm.2021.121046
   PubMedGoogle Scholar
• Patil SM, Barji DS, Aziz S, et al. Pulmonary delivery of spray-dried Nisin ZP antimicrobial peptide for non-small cell lung cancer (NSCLC) treatment. Int J Pharm. 2023;634:122641. doi:10.1016/j.ijpharm.2023.122641
   PubMedGoogle Scholar
• Dacomitinib drug bank online [Internet]. 2023. Available from: https://go.drugbank.com/drugs/DB11963
   Google Scholar
• Emami F, Mostafavi Yazdi SJ, Na DH. Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery. J Pharm Investig. 2019;49:427–442. doi:10.1007/s40005-019-00443-1
   Google Scholar
• Pourtalebi Jahromi L, Ghazali M, Ashrafi H, et al. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. Heliyon. 2020;6:e03451. doi:10.1016/j.heliyon.2020.e03451
   PubMed Web of Science ®Google Scholar
• Chou AJ, Gupta R, Bell MD, et al. Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer. 2013;60:580–586. doi:10.1002/pbc.24438
   PubMed Web of Science ®Google Scholar
• Wittgen BPH, Kunst PWA, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:2414–2421. doi:10.1158/1078-0432.CCR-06-1480
   PubMed Web of Science ®Google Scholar
• Otterson GA, Villalona-Calero MA, Sharma S, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:1246–1252. doi:10.1158/1078-0432.CCR-06-1096
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004;10:2319–2326. doi:10.1158/1078-0432.CCR-0929-3
   PubMed Web of Science ®Google Scholar
• Wauthoz N, Rosière R, Amighi K. Inhaled cytotoxic chemotherapy: clinical challenges, recent developments and future prospects. Expert Opin Drug Deliv. 2021;18:333–354. doi:10.1080/17425247.2021.1829590
   PubMedGoogle Scholar
• Singh R, Kesharwani P, Mehra NK, et al. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev Ind Pharm. 2015;41:1888–1901. doi:10.3109/03639045.2015.1019355
   PubMed Web of Science ®Google Scholar
• Dillen K, Vandervoort J, Van den Mooter G, et al. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm. 2004;275:171–187. doi:10.1016/j.ijpharm.2004.01.033
   PubMed Web of Science ®Google Scholar
• Anwer MK, Jamil S, Ansari MJ, et al. Development and evaluation of olmesartan medoxomil loaded PLGA nanoparticles. Mater Res Innov. 2016;20:193–197. doi:10.1179/1433075X15Y.0000000049
   Google Scholar
• Siegel SJ, Kahn JB, Metzger K, et al. Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm. 2006;64:287–293. doi:10.1016/j.ejpb.2006.06.009
   PubMed Web of Science ®Google Scholar